Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma

Japanese Journal of Cancer Research

Volumn 89, Issue 7, 1998, Pages 696-702

  Fujimoto, Hisao ^a   Sasaki, Ji Ichiro ^a   Matsumoto, Mitsuhiro ^a   Suga, Moritaka ^a   Ando, Yukio ^a   Iggo, Richard ^b   Tada, Mitsuhiro ^c   Saya, Hideyuki ^a   Ando, Masayuki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Lung adenocarcinoma; Nitric oxide; Nitric oxide synthase; p53; Yeast functional assay

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DNA DAMAGE; DNA SEQUENCE; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 0031712528     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb03273.x     Document Type: Article

References (33)

1. Minna, J. D. The molecular biology of lung cancer pathogenesis. Chest, 103, 449-456 (1993).
2. Valaitis, J., Warren, S. and Gamble, D. Increasing incidence of adenocarcinoma of the lung. Cancer, 47, 1042-1046 (1981).
3. Ohshima, H. and Bartsch, H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res., 305, 253-264 (1994).
4. Nathan, C. and Xie, Q. W. Nitric oxide synthases: roles, tools, and controls. Cell, 78, 915-918 (1994).
5. Amber, I. J., Hibbs, J. B., Jr., Taintor, R. R. and Vavrin, Z. The L-arginine dependent effector mechanism is induced in murine adenocarcinoma cells by culture supernatant from cytotoxic activated macrophages. J. Leukoc. Biol., 43, 187-192 (1988).
6. Radomski, M. W., Jenkins, D. C., Holmes, L. and Moncada, S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res., 51, 6073-6078 (1991).
7. Sherman, P. A., Laubach, V. E., Reep, B. R. and Wood, E. R. Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line. Biochemistry, 32, 11600-11605 (1993).
8. Thomsen, L. L., Lawton, F. G., Knowles, R. G., Beealey, J. E., Riveros, M. V. and Moncada, S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res., 54, 1352-1354 (1994).
9. Cobbs, C. S., Brenman, J. E., Aldape, K. D., Bredt, D. S. and Israel, M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res., 55, 727-730 (1995).
10. Thomsen, L. L., Miles, D. W., Happerfield, L., Bobrow, L. G., Knowles, R. G. and Moncada, S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer, 72, 41-44 (1995).
11. Fujimoto, H., Ando, Y., Yamashita, T., Teruzaki, H., Tanaka, Y., Sasaki, J., Matsumoto, M., Suga, M. and Ando, M. Nitric oxide synthase activity in human lung cancer. Jpn. J. Cancer Res., 88, 1190-1198 (1997).
12. Wink, D. A., Kasprzak, C. M., Maragos, C. M., Elespuru, R. K., Misra, M., Dunams, T. M., Cebula, T. A., Koch, W. H., Andrews, A. W., Allen, J. S. and Keefer, L. K. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science, 254, 1001-1003 (1991).
13. Nguyen, T., Brunson, D., Crespi, C. L., Penman, B. W., Wishnock, J. S. and Tannenbaum, S. R. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc. Natl. Accad. Sci. USA, 89, 3030-3034 (1992).
14. Denissenko, M. F., Pao, A., Tang, M. and Pfeifer, G. P. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in p53. Science, 274, 430-432 (1996).
15. Hollstein, M., Shomer, B., Greenblatt, M., Soussi, T., Hovig, E., Montesano, R. and Harris, C. C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res., 24, 141-146 (1996).
16. Murata, J., Tada, M., Iggo, R. D., Swamura, Y., Shinohe, Y. and Abe, H. Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat. Res., 379, 211-218 (1997).
17. Flaman, J. M., Frebourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P., Shappino, A. P., Limacher, J. M., Bron, L., Benhattar, J., Tada, M., Van Meir, E. G., Estreicher, A. and Iggo, R. D. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA, 92, 3963-3967 (1995).
18. Beahrs, O. H., Henson, D. E., Hutter, R. V. P. and Kennedy, B. J. "Manual for Staging of Cancer," 4th Ed., pp.115-122 (1992). American Joint Committee on Cancer, Philadelphia.
19. World Health Organization. The World Health Organization histological typing of lung cancer. Am. J. Clin. Pathol., 77, 123-136 (1982).
20. Bredt, D. S. and Snyder, S. H. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc. Natl. Acad. Sci. USA, 86, 9030-9033 (1989).
21. Tada, M., Iggo, R. D., Ishii, N., Shinohe, Y., Sakuma, S., Estreicher, A., Swamura, Y. and Abe, H. Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int. J. Cancer, 67, 447-450 (1996).
22. Ishioka, C., Frebourg, T., Yan, Y. X., Vidal, M., Friend, S. H., Schmidt, S. and Iggo, R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet., 5, 124-129 (1993).
23. Ward, A. C. Single-step purification of shuttle vectors from yeast for high frequency back-transformation into E. coli. Nucleic Acids Res., 18, 5319 (1990).
24. Hiyoshi, H., Matsuno, Y., Kato, H., Shimosato, Y. and Hirohashi, S. Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn. J. Cancer Res., 83, 101-106 (1992).
25. Liu, R.H., Jacob, J. R., Hotchkiss, J. H., Cote, P. J., Gerin, J. L. and Tennant, B. C. Woodchuck hepatitis virus surface antigen induces nitric oxide synthesis in hepatocytes: possible role in hepatocarcinogenesis. Carcinogenesis, 15, 2875-2877 (1994).
26. Boughton-Smith, N. K., Evans, S. M., Hawkey, C. J., Cole, A. T., Balsitis, M., Whittle, B. J. and Moncada, S. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet, 342, 338-340 (1993).
27. Greenblatt, M. S., Bennett, W. P., Hollstein, M. and Harris, C. C. Mutation in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878 (1994).
28. Tornaletti, S. and Pfeifer, G. P. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene, 10, 1493-1499 (1995).
29. Lindahl, T. Instability and decay of the primary structure of DNA. Nature, 362, 709-715 (1993).
30. Sato, S., Nakamura, Y. and Tsuchiya, E. Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res., 54, 5652-5655 (1994).
31. Shimosato, Y., Noguchi, M. and Matsuno, Y. Adenocarcinoma of the lung: its development and malignant progression. Lung Cancer, 9, 99-108 (1993).
32. Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K. V., Hamilton, S. and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50, 7717-7722 (1990).
33. Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavanee, W. and Vogelstein, B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature, 355, 846-847 (1992).